Disk diffusion susceptibility test development for the new glycylcycline, GAR-936
- 1 November 1999
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 35 (3), 249-252
- https://doi.org/10.1016/s0732-8893(99)00090-5
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolatesDiagnostic Microbiology and Infectious Disease, 2000
- In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9- t -Butylglycylamido Derivative of Minocycline (GAR-936)Antimicrobial Agents and Chemotherapy, 1999
- Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycylcyclinesJournal of Antimicrobial Chemotherapy, 1995
- N,N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocciAntimicrobial Agents and Chemotherapy, 1994
- In vitro activities of two glycylcyclines against gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1994
- Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclinesJournal of Medicinal Chemistry, 1994
- In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclinesAntimicrobial Agents and Chemotherapy, 1993
- In vitro activity of DMG-mino and DMG-DM Dot, two new glycylcyclines, against anaerobic bacteriaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1993